Summary: Rivastigmine (Exelon - Novartis) is the second cholinesterase inhibitor marketed for symptomatic treatment of mild to moderately severe Alzheimer\\\'s dementia, and follows donepezil (Aricept - Eisai; Pfizer). Previously, we have been \\\"unconvinced of the value of donepezil in routine clinical practice\\\". Rivastigmine has been promoted with the slogan \\\"Beyond cognition: improving functional ability\\\". Does rivastigmine offer useful benefits in Alzheimer\\\'s disease?
- 0 Hits
- Bury
- 0 Favorites
- Add to favorite